Janagliflozin

Janagliflozin is a medication used for the treatment of Type 2 diabetes. It belongs to the class of drugs known as SGLT2 inhibitors, which work by preventing the kidneys from reabsorbing glucose back into the blood, thereby promoting the excretion of glucose through urine.

Mechanism of Action

Janagliflozin works by inhibiting the SGLT2 protein in the kidneys. This protein is responsible for approximately 90% of the reabsorption of glucose from the glomerular filtrate back into the blood. By inhibiting this protein, Janagliflozin causes an increase in the excretion of glucose in the urine, thereby reducing blood glucose levels.

Uses

Janagliflozin is used in the management of Type 2 diabetes. It is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Side Effects

Common side effects of Janagliflozin include urinary tract infections, increased urination, and yeast infections in women. Serious side effects may include Ketoacidosis, kidney problems, and low blood sugar.

Contraindications

Janagliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis. It is also contraindicated in patients with a history of hypersensitivity reaction to Janagliflozin.

Interactions

Janagliflozin may interact with other medications such as diuretics, insulin, and sulfonylureas. It is important to inform your healthcare provider about all the medications you are currently taking.

See Also

• Sodium-glucose cotransporter 2 inhibitors
• Type 2 diabetes

Janagliflozin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia